The group that sets-up our Myeloma Cure Panel broadcasts and works to help publicize clinical trials, Cure Talk/TrialX, is running an interesting ASH review on their website. It features myeloma specialists Dr. Berenson, Dr Vij--and ME! Guess I'm moving up in the world! We were all asked if we could give a 5 point summary
Yesterday I queried about my therapy choices if and when my multiple myeloma starts to creep back: A) Do I try Velcade? B) Join a clinical study using one of the new novel therapy agents, alone or in combination? Or C) Do I reluctantly undergo a stem cell transplant (SCT)?I answered those questions this way:
Yesterday I began to describe the anti-myeloma strategy I expect to use once my multiple myeloma returns. As my myeloma slowly (very slowly, thank God!) begins to creep back, I am facing a number of important choices. Do I increase my Revlimid dose and frequency—then add dex to try and knock the cancer back again?
Before we move on, I wanted to share some of Dr. Ravi Vij's thoughts about UAMS—the University of Arkansas Medical Center. Myeloma docs and researchers there have been developing an aggressive form of anti-myeloma treatment called Total Therapy (TT). Arkansas myeloma specialist, Dr. Barlogie, and other UAMS myeloma researchers are best known for helping newly